Probiotic-related bacteremia after major hepatectomy for biliary cancer: a report of two cases

Mitsuhiro Shimura, Masamichi Mizuma*, Kei Nakagawa, Shuichi Aoki, Takayuki Miura, Tatsuyuki Takadate, Kyohei Ariake, Shimpei Maeda, Kei Kawaguchi, Kunihiro Masuda, Masaharu Ishida, Hideo Ohtsuka, Takanori Morikawa, Takashi Kamei and Michiaki Unno

Abstract

Background: Probiotics have been reported to be beneficial for the prevention of postoperative complications and are often used during the perioperative period. Among the probiotic-related adverse events, bacteremia is rare. Here, we report two cases of probiotic-related bacteremia after major hepatectomy for biliary cancer.

Case presentation 1: A 74-year-old man was referred to our hospital to be treated for gallbladder cancer. Neoadjuvant chemotherapy, two courses of gemcitabine plus S-1 combination therapy, was administered. Extended right hepatectomy with caudate lobectomy, extrahepatic bile duct resection and biliary reconstruction were performed 3 weeks after chemotherapy. Probiotics, Clostridium butyricum (C. butyricum) MIYAIRI 588, were administered 6 days before surgery and continued after surgery. Sepsis of unknown origin occurred 17 days after surgery and developed into septic shock. C. butyricum was detected in blood cultures at postoperative day 26 and 45. After stopping the probiotic agent, C. butyricum was undetectable in the blood cultures. The patient died due to an uncontrollable sepsis 66 days after surgery.

Case presentation 2: A 63-year-old man with diabetes mellitus whose past history included total colectomy, papilllectomy, and Frey's operation at the age of 19, 34 and 48, respectively, was referred to our hospital to be treated for perihilar cholangiocarcinoma. Extended left hepatectomy with caudate lobectomy, extrahepatic bile duct resection and reconstruction of bile duct were performed. Probiotics were administered during the perioperative period. Combined probiotics that included lactomin, amylolytic bacillus and C. butyricum, were given before surgery. C. butyricum MIYAIRI 588 was given after surgery. Sepsis occurred 16 days after surgery and developed to respiratory failure 8 days later. Blood culture at postoperative day 25 revealed Enterococcus faecalis and C. butyricum. After the probiotics were stopped at postoperative day 27, C. butyricum was not detected in the blood culture. The general condition improved with intensive care. The patient was transferred to another hospital for rehabilitation at postoperative day 156.

Conclusion: It should be noted that the administration of probiotics in severe postoperative complications can lead to probiotic-related bacteremia.

Keywords: Probiotics, Bacteremia, Sepsis, Postoperative complication, Clostridium butyricum

*Correspondence: masamichi@surg.med.tohoku.ac.jp
Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiriyomachi, Aobaku, Sendai 980-8574, Japan

Background

Probiotics, defined as “Live microorganisms which when administered in adequate amounts confer a health benefit on the host” by the World Health Organization and Food and Agricultural Organization of the United Nations [1],
are used in clinical settings worldwide for their protective effect against infection. In gastrointestinal surgery, probiotics have been reported to reduce postoperative infectious complications and are therefore widely administered during the perioperative period [2–6].

Probiotics are generally considered safe to use. However, a risk of probiotics-related infection, especially in patients with a poor immune condition, has been pointed out because probiotics are live microorganisms [7, 8]. Although probiotics-related bacteremia is rare, it can lead to fatal conditions [9]. Here, we present two cases of probiotics-related bacteremia that occurred during the treatment for sepsis after major hepatectomy with resection of extrahepatic bile duct for biliary cancer.

Case presentations

Case 1

A 74-year-old man with hypertension visited a previous hospital due to upper abdominal pain, appetite loss and nausea for 3 months. The patient had a past history of sigmoid colon and prostate cancer at the age of 50 and 68, respectively. The patient was referred to our hospital for further examinations and treatment. Enhanced computed tomography (CT) scan revealed a tumor of the gallbladder with invasion to the liver parenchyma, spreading to the junction of the cystic duct, and in contact with the right hepatic artery (Fig. 1). The biopsy of the bifurcation of the hepatic duct histologically demonstrated adenocarcinoma. The patient was diagnosed as gallbladder cancer spreading to the perihilar bile duct. The patient received percutaneous transhepatic portal vein embolization for the right liver. After 1 week, neoadjuvant chemotherapy (NAC) with gemcitabine plus S-1 was started and was administered for 6 weeks. The patient underwent endoscopic biliary drainage (EBD) 1 week before surgery due to obstructive jaundice. Preoperative screening cultures of the nasopharynx and bile juice revealed no specific findings. Preoperative blood test showed liver disorder (AST 42 U/l, ALT 87 U/l), malnutrition (ALB 3.0 g/dl, pre-albumin 15.6 mg/dl, retinol binding protein (RBP) 2.4 mg/dl) and anemia (Hb 8.4 g/dl). C-reactive protein (CRP) was slightly elevated (0.6 mg/dl). Total cholesterol (T-Chol) was 154 mg/dl. The percentages of neutrophils and lymphocytes were 46.8% and 29.8%, respectively. Indocyanine green clearance of the predicted remnant liver (ICG-Krem) was 0.052. Extended right hepatectomy with caudate lobectomy, extrahepatic bile duct resection and biliary reconstruction were performed 3 weeks after NAC. Operating time was 464 min, and operative blood loss was 865 ml. According to the TNM classification of malignant tumors in the eighth edition of the Union for International Cancer Control (UICC), histological examination demonstrated ypT3N1M0 and R0. Figure 2 shows the perioperative clinical course. Probiotics *Clostridium butyricum* (*C. butyricum*) MIYAIRI 588 were started from 6 days before hepatectomy. The postoperative course went well without bile or anastomotic leakage until postoperative day 16. The patient had a high fever of 40 °C with *Enterococcus faecium* and *Enterobacter cloacae* positive in two independent blood cultures on postoperative day 17 (Table 1), progressing to septic shock on postoperative day 20. The origin of the infection was unknown. Antibiotics and antifungal drugs were administered according to the results of the drug sensitivity test (Fig. 2). Continuous hemodiafiltration was started from 21 days after surgery. In blood cultures at postoperative day 26, two of two sets were positive for *Enterococcus faecium*, while one of two sets was positive for *C. butyricum* (Table 1). Although *C. butyricum* might have been from the probiotics, we thought it was from contamination because *C. butyricum* was not positive in 2 sets of blood cultures. The serum procalcitonin (PCT) value was 1.0 ng/ml at postoperative day 26 (Fig. 3). Consequently, the probiotics continued to be administered. The next blood cultures detected no *C. butyricum*. Antibiotic-resistant lactic acid bacteria (ARLAB), *Enterococcus faecalis* 129 BIO 3B-R, were additionally administered from 29 days after surgery. *C. butyricum* was observed in the two sets of blood cultures 45 days after surgery, showing the extremely increased serum PCT value (221.0 ng/ml) (Fig. 3). Probiotic-related bacteremia derived from *C. butyricum* MIYAIRI 588 was strongly suspected. Therefore, it was stopped immediately after the results were obtained. In the next blood culture, *C. butyricum* was not detected. The patient eventually died on postoperative day 66 due to uncontrollable sepsis.
Case 2

A 63-year-old man with diabetes mellitus visited a previous hospital due to a high-grade fever as the chief complaint. The patient had past histories of surgery: total colectomy for familial adenomatous polyposis at the age of 19, papillectomy with papilloplasty for a duodenal papillary tumor at the age of 34, and Frey’s operation for chronic pancreatitis at the age of 48. The patient was regularly taking combined probiotics, *Enterococcus faecium* T-110, *C. butyricum* TO-A, and *Bacillus subtilis* TO-A, before surgery. The patient was referred to our hospital for further examinations and treatment. Enhanced CT scan showed dilatation of the bile duct in the left liver and a mildly enhanced tumor in the dilatation origin (Fig. 4a). Magnetic resonance cholangio-pancreatography (MRCP) revealed a defect from the common hepatic duct to the left hepatic duct (Fig. 4b). Biopsy of the tumor histologically demonstrated adenocarcinoma. The patient was diagnosed with perihilar cholangiocarcinoma. EBD in the left hepatic duct was performed to avoid repeated cholangitis. *Pseudomonas aeruginosa*, coagulase-negative *Staphylococcus* and a yeast-like fungus were observed in the preoperative nasopharyngeal screening cultures (Table 2). Preoperative culture of the bile juice showed various types of bacteria including *Pseudomonas aeruginosa* (Table 2). The preoperative blood test showed malnutrition (ALB 3.4 g/dl, pre-albumin 19.3 mg/dl, RBP 2.0 mg/dl), anemia (Hb 10.4 g/dl), and no jaundice (total-bilirubin 0.8 mg/dl). CRP level was within the normal range (0.01 mg/dl). T-Chol value was 127 mg/dl. The percentages of neutrophils and lymphocytes were 61.3% and 32.2%, respectively. Extended left hepatectomy with caudate lobectomy, extrahepatic bile duct resection and biliary reconstruction were performed. The operating time was 676 min, and the operative blood loss was 2396 ml. Histological examination demonstrated pTisN0M0. Surgical margin of the hilar bile duct was pathologically positive. Probiotic *C. butyricum* MIYAIRI 588 was started from postoperative day 1. The postoperative course went well without bile or anastomotic leakage until postoperative day 14. A high fever above 38 °C of unknown origin was observed day after day from postoperative day 15. *Klebsiella pneumonia* and *Enterococcus faecium* were identified from blood cultures on postoperative day 17 (Table 3). Meropenem (MEPM), levofloxacin (LVX) and vancomycin (VCM) were intravenously administered according to the drug sensitivity. However, the general condition became worse and progressed to respiratory failure, requiring mechanical ventilation at postoperative day 25 (Fig. 5). Blood cultures at postoperative day 25 revealed that *Enterococcus faecalis* and *C. butyricum* were positive in both of the two sets (Table 3), showing elevated serum PCT value (11.5 ng/ml) (Fig. 6). Probiotic-related bacteremia due to bacterial translocation was suspected as the infection route of *C. butyricum*. Thus, *C. butyricum* MIYAIRI 588 was stopped at

---

**Fig. 2** Postoperative course of case 1. Asterisks indicate blood culture tests. Bold asterisks highlighted in gray indicate positive blood culture of *Clostridium butyricum*. ABPC, ampicillin; ARLAB, antibiotic-resistant lactic acid bacteria; *C. butyricum*, *Clostridium butyricum*; CHDF, continuous hemodiafiltration; CMZ, cefmetazole; DAP, daptomycin; DIC, disseminated intravascular coagulation; EBD, endoscopic biliary drainage; ICU, intensive care unit; MCFG, micafungin; PIPC/TAZ, piperacillin/tazobactam; SBT/CPZ, sulbactam/cefoperazone; VCM, vancomycin hydrochloride
postoperative day 27. Consequently, no *C. butyricum* was detected in the blood culture at postoperative day 30 (Table 3). This postoperative infectious complication improved with long-term intensive care. Although *C. butyricum* MIYAIRI 588 was administered at postoperative day 94 again, subsequent blood cultures showed no *C. butyricum*. The patient was transferred to another hospital for rehabilitation at postoperative day 156.

### Identifying colonies isolated from blood cultures in the two cases

Experiments to identify the colonies isolated from blood cultures in the two cases were conducted with the support of Miyarisan Pharmaceutical Co., Ltd. Samples at postoperative day 26 and 45 in case 1 and at postoperative day 25 in case 2 were examined. At first, 16S ribosomal RNA sequencing was performed. Then, sequence similarity was searched with Basic Local Alignment Search Tool (BLAST) of the National Center for Biotechnology Information (NCBI). From the sequencing analysis, all samples were identified as *C. butyricum*. Second, a cross-streak method using bacteriophage, phage KM1, was employed [10]. Positive and negative controls were *C. butyricum* MIYAIRI 588 and *C. butyricum* ATCC 19398T, respectively. In the result, none of the samples including the positive control grew in the phage zone, whereas the negative control did (data not shown). Therefore, the bacteria isolated from the blood cultures were very likely to be *C. butyricum* MIYAIRI 588 in all samples.

### Discussion

The present two cases showed bacteremia of *C. butyricum* during the treatment of sepsis after major hepatectomy for biliary cancer. Blood culture after stopping probiotic *C. butyricum* MIYAIRI 588 demonstrated no *C. butyricum* in both cases. Moreover, experiments to identify the bacteria isolated from the blood cultures revealed that they were very likely to be *C. butyricum* MIYAIRI 588 in both cases. Taken together, the present cases were diagnosed as probiotic-related bacteremia. Probiotic-related bacteremia is rare, even in a perioperative situation. In the last two decades, incidence of probiotic-related bacteremia after major hepatectomy for biliary cancer is 0.6% in our institute. Although probiotics are widely used during the perioperative period to prevent surgical infectious complications, probiotic-related bacteremia should be noted as one of the adverse events from the use of probiotics.

Boyle et al. have proposed risk factors for probiotics-related sepsis as follows: major risk factors are compromised immunity and premature infants. Minor risk factors were central venous catheter, impaired intestinal epithelial barrier, administration of probiotics by jejunostomy, concomitant administration of broad-spectrum

### Table 1  Postoperative culture test of case 1

| Collection date (postoperative day) | Sample | Detected bacteria |
|------------------------------------|--------|------------------|
| 18                                 | Blood  | *Enterococcus faecium*<sup>b</sup> |
| 21                                 | Blood  | *Enterococcus faecium*<sup>b</sup> |
| 21                                 | Stool  | *Enterococcus sp.* |
| 26                                 | Blood  | *Enterococcus faecium*<sup>b</sup> |
| 26                                 | Sputum | Normal flora |
| 32                                 | Blood  | Negative<sup>c</sup> |
| 33                                 | Blood  | *Enterococcus faecium*<sup>c</sup> |
| 36                                 | Stool  | *Enterococcus sp.* |
| 38                                 | Blood  | *Staphylococcus capitis*<sup>b</sup> |
| 42                                 | Blood  | *Candida albicans*<sup>b</sup> |
| 45                                 | Blood  | *Candida albicans*<sup>b</sup> |
| 48                                 | Sputum | *Candida albicans* |
| 50                                 | Blood  | *Candida albicans*<sup>c</sup> |

<sup><sup>a</sup></sup> Positive in one of two sets  
<sup>b</sup> Positive in both of two sets  
<sup>c</sup> One set examined
antibiotics to which probiotics are resistant, probiotics with properties of high mucosal adhesion or known pathogenicity and cardiac vascular disease [8]. Our two cases were debilitated due to major hepatectomy and subsequent severe sepsis. Moreover, they had a damaged intestinal epithelial barrier and concomitant administration of broad-spectrum antibiotics. Hence, these situations are thought to have caused bacterial translocation, leading to probiotic-related bacteremia.

Probiotics-related bacteremia is a rare adverse event. A systematic review revealed that in five cases (0.3%) of 1530 cancer patients in 17 studies there were probiotic-related bacteremia/fungemia/positive blood cultures [11]. Lactobacillus species, especially Lactobacillus rhamnosus, have been reported to be the most common pathogen among probiotic-related bacteria [8, 12, 13]. A PubMed search by the keyword of "Clostridium butyricum" and "bacteremia" or "sepsis" revealed no bacteremia.
emerging from probiotic *C. butyricum*. The present cases are the first report of bacteremia of probiotic *C. butyricum*. *C. butyricum* is a kind of indigenous bacteria isolated from 10 to 20% of human feces [14]. Therefore, in cases with positive blood culture of *C. butyricum* during the administration of probiotics that include it, it is necessary to consider indigenous bacteria as the origin in addition to the use of probiotics. Further examinations, such as sequencing analysis and a cross-streak method as in the present cases, are necessary for the determination of probiotic-related bacteremia.

In the present cases, bacterial translocation was inferred to have led to probiotic-related bacteremia. In addition to *C. butyricum*, other microorganisms were simultaneously identified in the blood cultures. *C. butyricum* may not be pathogenic in the bloodstream because of obligate anaerobes. The previous report, which demonstrated that *C. butyricum* MIYAIRI 588 has no genes for *Clostridium* toxins, supports the safety of *C. butyricum* MIYAIRI 588 from molecular biological assessment [15]. Also, *C. butyricum* MIYAIRI 588 has been reported to be susceptible to commonly used antibiotics, including PIPC/TAZ, VCM, MEPM and LVX, which were administered in the present cases [15, 16]. Therefore, if *C. butyricum* isolated from the blood of the present cases is *C. butyricum* MIYAIRI 588, it is presumed to have been in the state of spores, which are resistant to antibiotics and have an extremely low possibility of being pathogenic. Taken together, *C. butyricum* MIYAIRI 588 may not have pathogenicity in cases of probiotic-related bacteremia that occur during the administration of sensitive antibiotics. However, the state of probiotic-related bacteremia may indicate the likelihood of passage of other pathogenic bacteria across the intestinal epithelium into the bloodstream, namely, the likelihood of bacterial translocation. On the other hand, various reports have shown

### Table 2 Preoperative culture test of case 2

| Sample          | Detected bacteria                        |
|-----------------|------------------------------------------|
| Throat swab     | Normal flora                             |
|                 | *Pseudomonas aeruginosa*                 |
|                 | Yeast-like fungus                        |
| Nasal swab      | Normal flora                             |
|                 | *Coagulase (−) Staphylococcus*           |
|                 | *Pseudomonas aeruginosa*                 |
| Bile            | *Klebsiella pneumoniae*                  |
|                 | *Escherichia coli*                       |
|                 | *Stenotrophomonas maltophilia*           |
|                 | *Klebsiella oxytoca*                     |
|                 | *Candida albicans*                       |

### Table 3 Postoperative culture test of case 2

| Collection date (postoperative day) | Sample | Detected bacteria                                                                 |
|-------------------------------------|--------|-----------------------------------------------------------------------------------|
| 9                                   | Bile   | Acinetobacter sp. (MBL)                                                           |
|                                     |        | *Enterobacter faecium*                                                           |
|                                     |        | *Escherichia coli*                                                               |
|                                     |        | *Klebsiella pneumoniae*                                                          |
|                                     |        | *Pseudomonas aeruginosa*                                                         |
|                                     |        | *Candida albicans*                                                               |
| 17                                  | Blood  | *Enterobacter faecium<sup>b</sup>*                                               |
|                                     |        | *Klebsiella pneumoniae<sup>b</sup>*                                              |
| 25                                  | Blood  | *Enterobacter faecalis<sup>b</sup>*                                              |
|                                     |        | *Clostridium butyricum<sup>b</sup>*                                              |
|                                     |        | *Enterobacter cloacae*                                                           |
| 25                                  | Stool  | *Enterococcus sp.*                                                               |
|                                     |        | *Enterobacter cloacae*                                                           |
|                                     |        | *Bacillus subtilis*                                                              |
|                                     |        | *Coagulase (−) Staphylococcus*                                                   |
|                                     |        | *Candida albicans*                                                               |
|                                     |        | *Candida parapsilosis*                                                           |
| 30                                  | Blood  | *Candida albicans<sup>a</sup>*                                                   |
| 34                                  | Stool  | *Enterococcus sp.*                                                               |
|                                     |        | *Acinetobacter baumannii complex*                                                |
|                                     |        | *Candida albicans*                                                               |
|                                     |        | *Candida parapsilosis*                                                           |
| 36                                  | Blood  | Negative<sup>b</sup>                                                             |
| 44                                  | Blood  | Negative<sup>b</sup>                                                             |
| 51                                  | Blood  | *Candida parapsilosis<sup>a</sup>*                                               |
| 57                                  | Blood  | *Candida parapsilosis<sup>b</sup>*                                               |
|                                     |        | *Candida albicans<sup>a</sup>*                                                   |
| 64                                  | Blood  | *Enterococcus faecium<sup>b</sup>*                                               |
| 72                                  | Blood  | Negative<sup>b</sup>                                                             |
| 78                                  | Urine  | *Candida parapsilosis*                                                           |
| 79                                  | Blood  | Negative<sup>b</sup>                                                             |
| 83                                  | Sputum | *Serratia marcescens*                                                            |
| 91                                  | Blood  | *Serratia marcescens<sup>b</sup>*                                                |
| 96                                  | Urine  | Negative                                                                         |
| 99                                  | Blood  | *Staphylococcus epidermidis<sup>a</sup>*                                          |
| 114                                 | Sputum | *Pseudomonas aeruginosa*                                                         |
|                                     |        | *Enterococcus sp.*                                                               |
|                                     |        | *Serratia marcescens*                                                            |
| 114                                 | Blood  | Negative<sup>b</sup>                                                             |

<sup>a</sup> Positive in one of two sets  
<sup>b</sup> Positive in both of two sets  
<sup>c</sup> One set examined

*MBL* metallo-β-lactamase
that probiotics are beneficial for bacterial translocation [17–19]. Thus, we should not be excessively reluctant to use probiotics because of the possibility of bacterial translocation, while being aware of probiotic-related bacteremia.

There is a limitation in the cross-streak method using phage KM1 performed in the present cases. That is, there may be bacteria other than C. butyricum MIYAIRI 588 that are sensitive to phage KM1.
Conclusion
We experienced two rare cases of probiotic-related bacteremia after major hepatectomy for biliary cancer. Probiotic-related bacteremia should be noted as one of the possible adverse events when using probiotics.

Abbreviations
ABPC: Ampicillin; ARDS: Acute respiratory distress syndrome; ARLAB: Antibiotic-resistant lactic acid bacteria; C. butyricum: Clostridium butyricum; CBCD: Clostridium butyricum combined drug; CMZ: Cefmetazole; CRP: C-reactive protein; CT: Computed tomography; DAP: Daptomycin; DIC: Disseminated intravascular coagulation; F-FLCZ: Fosfloxazone; ICG: Indocyanine green; ICU: Intensive care unit; L-AMB: Amphoterocin B (liposomal); LIX: Levofloxacin; MCFG: Micafungin; MEPM: Meropenem; MNZ: Metronidazole; NAC: Neoadjuvant chemotherapy; PCT: Procalcitonin; PIPC/TAZ: Piperacillin/tazobactam; RBP: Retinol-binding protein; RHA: Right hepatic artery; SBT/ABPC: Sulbactam/ampicillin; T-Chol: Total cholesterol; TEIC: Teicoplanin; VCM: Vancomycin hydrochloride.

Acknowledgements
We thank MIYARISAN PHARMACEUTICAL Company Limited for the in vitro identification experiments on the blood culture colonies.

Authors’ contributions
MS and MM wrote the paper. KN, SA, TMI, TT, KA, SM, KK, KM, MI, HO, TMo, TK and MU reviewed the manuscript, and revised it critically for important intellectual content. All authors read and approved the final manuscript.

Funding
Michiaki Unno: Management Expenses Grants from the Government of Japan to national university corporations supplied every fiscal year.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication was obtained from the patients before surgery.

Competing interests
The authors declare that they have no competing interests.

Received: 31 December 2020 Accepted: 24 May 2021
Published online: 01 June 2021

References
1. FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. 2001.
2. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg. 2005;390(2):104–13.
3. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg. 2006;244(5):706–14.
4. Liu Z, Qin H, Yang Z, Xia Y, Liu W, Yang J, et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery—a double-blind study. Aliment Pharmacol Ther. 2011;33(1):50–63.
5. Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012;343(3):199–205.
6. Zhang Y, Chen J, Wu J, Chalson H, Merigan L, Mitchell A. Probiotic use in preventing postoperative infection in liver transplant patients. Hepatobiliary Surg Nutr. 2013;2(3):142–7.
7. Kohari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: a review. Biomed Pharmacother. 2019;111:537–47.
8. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64 (quiz 446-7).
9. Costa RL, Moreira J, Lorenzo A, Lamas CC. Infectious complications following probiotic ingestion: a potentially underestimated problem? A systematic review of reports and case series. BMC Complement Altern Med. 2018;18(1):329.
10. Maeda A, Ishii K, Tanaka M, Mikam Y, Ara T, KM1, A, bacteriophage of Clostridium butyricum. J Gen Microbiol. 1986;132:2271–5.
11. Hedman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919–29.
12. Lioing MT. Safety of probiotics: translocation and infection. Nutr Rev. 2008;66(4):192–202.
13. Michael HL, Kelly RS, Charles RW, Michael LC, James C, Avinash KS. Lactobacillus species associated with probiotic therapy. Pediatrics. 2005;115(1):178–81.
14. Benno Y, Sawada K, Mitsuoka T. The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol Immunol. 1984;28(9):975–86.
15. Isa K, Oka K, Beauchamp N, Sato M, Wada K, Ohtani K, et al. Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo. Hum Exp Toxicol. 2016;35(8):818–32.
16. Yamaguchi T, Miura Y, Matsumoto T. Antimicrobial susceptibility of Enterococcus strains used in clinical practice as probiotics. J Infect Chemother. 2013;19(6):1109–15.
17. Sato J, Kanazawa A, Azuma K, Ikeda F, Goto H, Komiya K, et al. Probiotic reduces bacterial translocation in type 2 diabetes mellitus: a randomised controlled study. Sci Rep. 2017;7(1):12115.
18. Gunduz M, Murakami D, Gunduz I, Tamagawa S, Hiraoka M, Sugita G, et al. Recurrent bacterial translocation from gut and sepsis in Head and neck cancer patients and its prevention by probiotics. Med Hypotheses. 2018;120:124–7.
19. Celikkaya ME, Akcora B, Hakverdi S, Ozger B, Ulutas KT, Duren N. Effects of probiotic use on bacterial translocation in created rat models with biliary obstructions. Eurasian J Med. 2019;51(2):106–11.